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ABSTRACT The specificity of T cell-mediated immune
responses is primarily determined by the interaction between
the T cell receptor (TCR) and the antigenic peptide presented
by the major histocompatibility complex (MHC) molecules. To
refine our understanding of interactions between the TCR and
the antigenic peptide of vesicular stomatitis virus (VSV)
presented by the class I MHC molecule H-2Kb, we constructed
a TCR a chain transgenic mouse in a TCR a-deficient
background to define specific structural features in the TCR
b chain that are important for the recognition of the VSVy
H-2Kb complex. We found that for a given peptide, a peptide-
specific, highly conserved amino acid could always be iden-
tified at position 98 of the complementarity-determining
region 3 (CDR3) loop of TCR b chains. Further, we demon-
strated that substitutions at position 6, but not position 1, of
the VSV peptide induced compensatory changes in the TCR in
both the amino acid residue at position 98 and the length of
the CDR3b loop. We conclude that the amino acid residue at
position 98 of the CDR3b loop is a key residue that plays a
critical role in determining the specificity of TCR–VSV/H-2Kb
interactions and that a specific length of the CDR3b loop is
required to facilitate such interactions. Further, these find-
ings suggest that the a and b chains of TCRs interact with
amino acid residue(s) toward the N and C termini of the VSV
peptide, respectively, providing functional evidence for the
orientation of a TCR with its peptide/MHC ligand as observed
in the crystal structures of TCRypeptideyMHC complexes.
One of the central events in determining the specificity of T
cell-mediated cellular immune responses is the interaction
between the ab T cell receptor (TCR) and the major histo-
compatibility complex (MHC)/peptide complex. To generate
the TCR diversity needed for antigen recognition, sequences
encoding TCR a and b chain variable domains are formed
through DNA rearrangement, a process that fuses the variable
(V), diversity (D, b only), and joining (J) gene segments of
TCR a and b loci together (1, 2). The complementarity-
determining region 1 (CDR1, 6 amino acids in length) and
CDR2 (8–12 amino acids) stretches of TCR a and b chains are
encoded by germ-line V gene segments, whereas the CDR3
loops (6–13 amino acids) are encoded by the V(D)J junctions
derived from different germ-line V, D, and J segments and
N-additions. Due to the absence of somatic hypermutation in
TCR genes, such a mechanism limits the diversity of the CDR1
and CDR2 loops to the sequences present in the germ line and
makes the CDR3 loops the most diverse regions in TCR chains
(1). The striking concentration of TCR diversity in the CDR3
loops has led to the proposal that the CDR3 loops of TCRs
interact with antigenic peptides in the T cell recognition of the
peptideyMHC complex (1, 3, 4). The crystal structures of
TCRypeptideyMHC complexes support such a proposal (5, 6).
A number of structure–function studies have been carried
out to test in vivo the proposed CDR3–peptide interaction
(7–11). Using an approach analogous to the classical genetic
technique of second-site suppression, several groups showed
that alterations at the TCR-contacting residues of antigenic
peptides presented by class II MHC molecules elicited com-
pensatory changes in the CDR3 loop of the TCR a or b chain
(7, 8, 10). These results indicated that there are specific
interactions between the CDR3 loops of TCRs and the anti-
genic peptide presented by class II MHC molecules. On the
other hand, similar studies performed in the class I MHC
system to date did not find interactions between specific amino
acid residue(s) within the CDR3 loops and the peptides
presented by class I MHC molecules, although the studies
supported the idea that the CDR3 loops of TCRs were the
major determinants for recognizing the antigenic peptides
presented by class I MHC molecules (9, 11).
Although the solution of the crystal structure of TCRy
peptideyMHC complexes has provided a general outline of
interactions between TCRs and their cognate ligands, in vivo
functional studies are needed to define specific structural
features of TCR–peptide interactions important for the rec-
ognition of the peptideyMHC complex. We have developed a
model system for analyzing the specific features of TCRs of
cytotoxic T lymphocytes (CTLs) that recognize the antigenic
peptide (amino acid residues 52–59 of the nucleoprotein,
RGYVYQGL) of vesicular stomatitis virus (VSV) presented
by the class I MHC molecule H-2Kb. From the crystal structure
of the VSV peptideyH-2Kb complex (12, 13) as well as
functional studies (14), we identified amino acid residues at
positions 1, 4, and 6 of the VSV peptide as potential TCR-
contacting residues. Further, in a previous study (15), we found
that the Vb13 gene segment was used by 8 of 12 VSV-specific
T cell clones, suggesting that Vb13 plays an important role in
the T cell recognition of the VSV peptideyH-2Kb complex.
However, as different Va gene segments were employed in
these Vb131 VSV-specific CTL clones and there was a high
level of diversity in the CDR3 loops of TCR a and b chains
(15), it was difficult to rigorously establish a relationship
between the structure of the CDR3 loops of TCRs and the
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VSV peptide bound to the H-2Kb molecule. These results
impelled us to take a different approach to analyze the
TCR–VSV peptide interaction.
In this study, we generated TCR a chain transgenic mice in a
TCR a-deficient background and used these mice to further
analyze the interaction between the TCR b chain and the VSV
peptide. The use of a TCR a-deficient background ensured that
all mature T cells from our transgenic mice express identical TCR
a chains (the introduced TCR a chain transgene) on their
surfaces. When these mice were immunized with VSV peptide
variants altered at potential TCR-contacting residues identified in
our previous studies (13–15), the sequences of the TCR b chains
of T cells proliferating in response to the altered peptides could
then be analyzed to reveal changes that compensate for the
altered peptide residue. It was found that substitution at position
6 of the VSV peptide induced compensatory changes in the
CDR3b loops of TCRs from responding T cells. These included
peptide-specific, reciprocal charge changes in the amino acid
residue at position 98 of the CDR3b loops and alterations in the
length (i.e., the number of amino acids) of the CDR3b loops.
These findings allow us to conclude that the amino acid residue
at position 98 of the TCR CDR3b loop is a key residue that plays
a critical role in determining the specificity of the interaction
between the TCR b chain and the antigenic peptides presented
by the class I MHC molecule, and that a specific CDR3b length
is required to facilitate the interaction between a TCR and its
ligand.
MATERIALS AND METHODS
Preparation of mRNA and cDNA. mRNA was extracted
from 106 cells using the Oligotex Direct mRNA Kit (Qiagen).
Single-strand cDNA was made by reverse transcription of
mRNA using Moloney murine leukemia virus reverse tran-
scriptase and oligo(dT)15 as primer. Double-strand cDNA was
obtained by PCR amplification of single-strand cDNA using
Pfu DNA polymerase (Stratagene) and the specific PCR
primers (see below).
Construction of TCR a Chain Transgene. The TCR a chain
transgene was constructed by inserting the double-strand
cDNA of the VJ segment of the TCR a chain (Va2) of the
VSV peptide-specific CTL clone N30.7 (15) into the TCR a
chain shuttle vector (16), kindly provided to us by Mark Davis
(Stanford University). Two specific PCR primers for gener-
ating the double-strand cDNA of the VJ segment were 59
primer, aaactcgagacctgtgtggataaaaacctctctgattctggtttgc-
ttttctgtttccaagcagtacaggagaaacgtgaccagcg; and 39 primer,
aaaattgcggccgcttgggcccaagaaactgtcatcaaaacgtactggggctga-
ctgataccgtggt. The underlined nucleotides in the 59 and 39
primers represent restriction sites for XhoI and NotI, respec-
tively.
Generation of TCR a Chain Transgenic Mice. TCR a chain
(Va2) transgenic mice were generated by injecting purified
TCR a chain transgene DNA into F2 embryos of CBA and
C57BL/6 mice. Mice carrying the Va2 transgene were identi-
fied by Southern analysis of mouse tail DNA. To generate TCR
a chain transgenic mice in a TCR a-deficient background, the
Va2 transgenic mice were crossed for two generations with
TCR a-deficient mice (17) purchased from the Jackson Lab-
oratory. Southern analysis of mouse tail DNA was used to
identify mice that not only carried the introduced Va2 trans-
gene but also were homozygous for the disrupted TCR Ca
allele. These mice are referred to as TCRa2/2TgVa21 mice.
Southern Analysis of Mouse Tail DNA. Mouse tail DNA was
digested with BamHI, electrophoresed through 0.7% agarose
gels, and transferred to Hybond-N membranes (Amersham).
The hybridization probe was prepared by PCR using the TCR
a transgene construct as template and the following primers:
59 primer, ctggctagtccagagagttcc; 39 primer, ggccccattgctcttg-
gaatc, and labeled with 32P using Rediprime DNA labeling
system (Amersham). Rapid-hyb buffer (Amersham) was used
in all hybridizations, and the most stringent wash was per-
formed in 0.33 SSC (13 SSC 5 0.15 M sodium chloride/0.015
M sodium citrate, pH 7)/0.1% SDS at 65°C.
Generation of Peptide-Specific CTLs. Peptides were synthe-
sized and purified to .98% homogeneity by HPLC before being
used for immunization. TCRa2/2TgVa21 mice were immunized
in their hind footpads with 15 mg of peptide emulsified in
complete Freund’s adjuvant and boosted 1 week later with 15 mg
of peptide emulsified in incomplete Freund’s adjuvant. One week
after boost, spleen cells were cultured at 5 3 106/ml with 1 mM
peptide in 10 ml of Iscove’s MDM supplemented with 10%
heat-inactivated fetal bovine serum (HyClone) at 37°C under 9%
CO2 in air. Cytolytic assay, flow cytometry, and cell sorting were
performed after 5–6 days of culture.
Cytolytic Assay. CTL activity was measured in a 4-h 51Cr
release assay as described (18). The percentage of specific lysis
was calculated as [(experimental release-spontaneous re-
lease)/(total release-spontaneous release)] 3 100.
Fluorescence-Activated Cell Sorter (FACS) Analysis and
Cell Sorting. To detect surface expression of the Va2 trans-
gene, lymph node cells of 6- to 8-week-old mice were stained
with anti-Va2 (B20.1) and anti-pan TCR (H57–597) antibod-
ies for 30 min at 4°C. To determine the usage of different Vb
families in peptide-specific CTLs, CTLs were stained with
anti-CD8 (53–6.7) and a specific anti-Vb antibody. To obtain
pure populations of CD81Va21 T cells, peptide-specific CTLs
were stained with antibodies against Va2 and CD8. All
antibodies were purchased from PharMingen. FACS analysis
and cell sorting of stained cells were performed on a FACScan
and a FACStar (Becton Dickinson), respectively.
Analysis of TCR CDR3b Sequences. Double-strand cDNA of
TCR CDR3b loops of CD81Va21 cells was prepared as de-
scribed above. PCR primers used to generate the double-strand
cDNA were Vb7-specific primer, tacagggtctcacggaagaagc; Vb13-
specific primer, aggcctaaaggagctaactccac; Cb-specific primer,
cactgatgttctgtgtgacag. PCR products were cloned into pCR2.1
(Invitrogen), and the TCR CDR3b sequences in the resulting
plasmids were determined by DNA sequencing.
RESULTS
Generation of TCR a Chain Transgenic Mice in a TCR
a-Deficient Background. To analyze interactions between the
TCR b chain and the VSV peptide presented by the H-2Kb
molecule, the TCR a chain (Va2) from the VSV-specific CTL
clone N30.7 (15) was used to generate TCR a chain transgenic
mice. This particular TCR a chain was selected for two reasons.
First, it is paired with a Vb13 TCR b chain. It is significant that
Vb13 is used by 75% of VSV-specific CTL clones generated from
C57BL/6 mice and is believed to play an important role in the T
cell recognition of the H-2KbyVSV peptide complex (15). Sec-
ond, anti-Va2 antibodies are available for detecting the cell
surface expression of the Va2 transgene. To avoid the ambiguity
existing in the traditional TCR a chain transgenic mice, where T
cells can potentially express either the introduced TCR a trans-
gene or an endogenous TCR a gene or both, we crossed our Va2
transgenic mice with TCR a chain-deficient mice (17). Due to the
targeted disruption of the first exon of the endogenous TCR Ca
alleles, T cells from the resulting mice can only express the
introduced Va2 transgene on their surfaces. Accordingly, FACS
analysis showed that all peripheral T cells of TCRa2/2TgVa21
mice expressed the introduced Va2 transgene on their surfaces
(data not shown). Thus, these mice provide us with an animal
model for defining the specific features of the interaction between
the VSV peptide and the TCR b chain of specifically induced T
cells.
TCR b Chains of VSV Peptide-Specific CTLs Have a Highly
Conserved G97(V/T)98 Motif in the CDR3 Loop and a Constant
CDR3 Length. To reveal the features of TCRs interacting with
the VSV peptide presented by the H-2Kb molecule,
TCRa2/2TgVa21 mice were immunized with the VSV pep-
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tide, and the CDR3b sequences of TCR b chains of VSV
peptide-specific CTLs from four different mice were analyzed.
As shown in Fig. 1A, VSV peptide-specific CTLs can be
easily induced in TCRa2/2TgVa21 mice despite the fact that
the TCR of every T cell of these mice must use the introduced
Va2 transgenic a chain. This result indicates that endogenous
TCR b chains can functionally pair with the introduced Va2
transgene to recognize and respond to the VSV peptide. FACS
analysis using a panel of anti-Vb antibodies showed that, as in
normal C57BL/6 mice (15), Vb13 is used by more than 80% of
VSV peptide-specific CTLs from TCRa2/2TgVa21 mice
(data not shown). Further, analysis of CDR3 loops of TCR b
chains revealed two significant structural features (Table 1): 1)
almost all the CDR3b loops have a motif of Gly at position 97
and Val or Thr at position 98 [G97(V/T)98], despite the high
diversity of amino acid residues at other positions and in the
Jb usage, 2) the length of the CDR3b loop is 9 amino acids in
all sequenced TCR b chains when calculated from the amino
acid residue following the 94Ser to the amino acid residue
preceding the highly conserved Phe-Gly framework (19, 20).
Given the fact that these VSV-specific CTLs were generated
from four different mice, such data suggest that the VSV
peptide presented by the H-2Kb molecule specifically induced
T cells that have TCRs with a highly conserved CDR3b loop
in terms of the G97(V/T)98 motif and the CDR3 length.
Substitutions at Position 6 of the VSV Peptide Induce
Compensatory Changes in Both the Amino Acid Residue at
Position 98 and the Length of the CDR3 Loop of TCR b
Chains. Amino acid residues at positions 1, 4, and 6 of the VSV
peptide (RGYVYQGL) have been suggested to make contacts
with TCRs (12–14), indicating that alterations at these residues
may change or abolish the recognition of the altered peptide
by VSV-specific CTLs. Interestingly, the VSV-specific CTL
clone N30.7, whose TCR a chain was used to generate the
TCRa2/2TgVa21 mice, recognizes peptides with Ala (A) at
position 1 or 4 of the VSV peptide (AGYVYQGL or
RGYAYQGL) but fails to recognize the peptide with either
Ala (A) or Lys (K) at position 6 of the VSV peptide
(RGYVYAGL or RGYVYKGL) (15). This suggests that for
this TCR the amino acid residue at position 6 of the VSV
peptide could be the key residue determining the specificity for
interaction with the corresponding TCR.
To determine whether the amino acid residue at position 6
of the VSV peptide interacts with the b chain of TCRs, the
K6 peptide (RGYVYKGL) was used to immunize
TCRa2/2TgVa21 mice. Because the K6 peptide cannot be
recognized by N30.7 in vitro and all T cells from TCRa2/2
TgVa21 mice have the same TCR a chain as N30.7, the successful
induction of the K6-specific CTLs from TCRa2/2TgVa21 mice
(Fig. 1B) strongly suggests that the amino acid residue at position
6 of the VSV peptide interacts with the b chain of TCRs.
To reveal any changes induced in TCRs of K6 peptide-specific
CTLs that can compensate for the alteration (Q3K) at position
6 of the VSV peptide, we analyzed the CDR3b sequences of
TCRs of K6 peptide-specific CTLs from three different mice.
Because Vb13 was predominantly used by K6 peptide-specific
CTLs from TCRa2/2TgVa21 mice (data not shown), we focused
our analyses on the CDR3b sequences of TCRs of K6-specific,
Vb131 CTLs. As shown in Table 2, compared with those of VSV
peptide-specific CTLs, the CDR3b loops of TCRs of K6 peptide-
specific CTLs not only contained a new motif consisting of an Arg
(R) at position 97 and an Asp (D) at position 98 (i.e., R97D98
motif), but also had a longer CDR3b loop (10 or 11 amino acids).
Taken together with the data obtained from the VSV peptide-
specific CTLs (Table 1), these results suggest that the unique
motif at positions 97 and 98 of the CDR3b loop as well as the
specific CDR3b length of such TCRs are determined by the
existence of a particular amino acid at position 6 of the VSV
peptide recognized by CTLs.
Considering the fact that a negatively charged Asp (D) was
used at position 98 of the CDR3b loop for TCRs to interact with
the peptide that has a positively charged Lys (K) at position 6, it
is likely that there is a specific ionic interaction between these two
amino acid residues. To test whether the reciprocal ionic inter-
action would be found, E6 (RGYVYEGL) and D6 (RGYVY-
FIG. 1. Induction of peptide-specific CTLs in TCR a2/2Tg Va21
mice. TCR a2/2Tg Va21 mice were immunized with the VSV peptide
(A), the K6 peptide (B), the E6 peptide (C), or the K1 peptide (D).
After 1 week in vitro culture, the cytotoxic activity of T cells was
measured in a 4-h 51Cr-release assay using RMA/s cells incubated with
(F) or without (E) the immunizing peptide as target.
Table 1. CDR3b sequences of TCRs of VSV
peptide-specific CTLs
TCRa2y2TgVa21 mice were immunized with the VSV (wild-type)
peptide, and TCR CDR3b sequences of CTLs were determined after
1 week in vitro culture. The single-letter amino acid code is used for
all listed sequences. The conserved amino acid(s) is shown in boldface.
Amino acids preceding ‘‘LCAS’’ of Vb and following the highly
conserved ‘‘FG’’ of Jb are not shown. Freq. (frequency) column shows
the number of times each amino acid sequence was obtained and the
total number of sequences analyzed from that mouse.
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DGL) peptides, which have a negatively charged amino acid at
position 6 of the VSV peptide, were used to induce peptide-
specific CTLs in TCRa2/2TgVa21 mice (Fig. 1C), and the
CDR3b sequences of peptide-specific CTLs were analyzed. In
contrast to the predominant Vb13 usage (about 80%) in both
VSV peptide- and K6 peptide-specific CTLs, we observed that
most CD81 T cells (about 75%) of E6 or D6 peptide-specific
CTLs used Vb7 to pair with the introduced Va2 (A.M.K.,
unpublished results). More importantly, it was found that the
CDR3b loops of TCRs of E6 or D6 peptide-specific CTLs
contained a positively charged Arg (R), or occasionally Lys (K),
at position 98 and also contained more amino acids than those of
the CDR3b loop of TCRs recognizing the VSV peptide (Table
2). These results indicated that a reciprocal charge change in the
amino acid residue at position 98 of the CDR3b loop was made
by TCRs of E6 or D6 peptide-specific CTLs to compensate for the
alteration (Q3 E or Q3 D) at position 6 of the VSV peptide.
Such results support the suggestion that there is a specific
interaction between the amino acid residue at position 6 of the
VSV peptide and the amino acid residue at position 98 of the
CDR3b loop of TCRs.
Substitutions at Position 1 of the VSV Peptide Do Not Change
Either the Conserved G97(V/T)98 Motif or the Length of the
CDR3b Loop of TCR b Chains. To confirm our conclusion that
the changes observed in the CDR3b loop of TCRs in response to
variant peptides were specifically induced by substitutions at
position 6 of the VSV peptide, we next immunized TCRa2/2
TgVa21 mice with peptides altered at a position unlikely to
contact the TCR b chain. Several studies have demonstrated that
TCRs interact with the peptideyMHC complexes in a diagonal
orientation, in which the CDR3 loops of TCR a and b chains map
over the N and C termini of the peptide, respectively (5, 6, 10, 21).
Accordingly, if the amino acid residue at position 6 of the VSV
peptide interacts with the amino acid residue at position 98 of the
CDR3b loop of TCRs, as suggested from the above experiments,
the amino acid residue at position 1 of the VSV peptide is likely
to interact with the CDRa loops of TCRs. Therefore, substitu-
tions at position 1 of the VSV peptide should not induce changes
in the CDR3b loop of TCRs. To test this hypothesis,
TCRa2/2TgVa21 mice were immunized with I1 (IGYVYQGL)
or K1 (KGYVYQGL) peptides to elicit peptide-specific CTLs.
These two particular peptides were selected because they can be
recognized by N30.7 in vitro (F.W., unpublished results), thus
making it possible for us to obtain I1 or K1 peptide-specific CTLs
in TCRa2/2TgVa21 mice (Fig. 1D) even when the amino acid
residue at position 1 of the VSV peptide interacts with the
invariable transgenic TCR a chain.
As was the case for the VSV peptide-specific CTLs, Vb13
was predominantly used by both I1 and K1 peptide-specific
CTLs (data not shown). Further, compared with the CDR3b
sequences of the VSV peptide-specific CTLs, the CDR3b
sequences of TCRs of I1 and K1 peptide-specific CTLs (Table
3) not only contained the same G97(V/T)98 motif but also had
the same CDR3 length (9 amino acids), indicating that sub-
stitutions at position 1 of the VSV peptide did not induce
changes in the CDR3b loop of TCRs. Such results support the
argument that the compensatory changes in the CDR3b loop
of TCRs induced by substitutions at position 6 of the VSV
peptide reflect the specific interaction between the CDR3b
loop of TCRs and the amino acid residue at position 6 of the
VSV peptide bound to the H-2Kb molecule.
DISCUSSION
In the present study, we generated TCR a chain transgenic
mice in a TCR a-deficient background to define the details of
Table 2. CDR3b sequences of TCRs of K6, E6, or D6
peptide-specific CTLs
TCRa2y2TgVa21 mice were immunized with the K6, E6, or D6
peptide, and TCR CDR3b sequences of CTLs were determined after
1 week in vitro culture. The single-letter amino acid code is used for
all listed sequences. The conserved amino acid(s) is shown in boldface.
Amino acids preceding ‘‘LCAS’’ of Vb and following the highly
conserved ‘‘FG’’ of Jb are not shown. Freq. (frequency) column shows
the number of times each amino acid sequence was obtained and the
total number of sequences analyzed from that mouse.
Table 3. CDR3b sequences of TCRs of I1 or K1
peptide-specific CTLs
TCRa2y2TgVa21 mice were immunized with the I1 or K1 peptide,
and TCR CDR3b sequences of CTLs were determined after 1 week
in vitro culture. The single letter amino acid code is used for all listed
sequences. The conserved amino acid(s) is shown in boldface. Amino
acids preceding ‘‘LCAS’’ of Vb and following the highly conserved
‘‘FG’’ of Jb are not shown. Freq. (frequency) column shows the
number of times each amino acid sequence was obtained and the total
number of sequences analyzed from that mouse.
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the interaction between the TCR b chain and the VSV peptide
presented by the H-2Kb molecule. Two previous findings
indicated that such an approach would require the use of mice
with a TCR a-deficient background. First, the expression of a
functionally rearranged TCR a chain transgene does not
prevent the rearrangement and expression of endogenous
TCR a chain genes (16, 22–25). Second, two different TCR a
chains can be simultaneously expressed on the surface of a T
cell (26–28). Thus, T cells from TCR a chain transgenic mice
that are not in a TCR a-deficient background can potentially
express either the introduced TCR a transgene or an endog-
enous TCR a gene or both. Such a complicated uncontrolled
background of TCR a chain expression makes it very difficult
to use such mice to map the peptide-contacting residue(s) in
the TCR b chain because the interpretation of the data
requires that each TCR b chain be paired with an identical
TCR a chain. The use of TCR a chain transgenic mice in a
TCR a-deficient background has enabled us to reveal several
significant features of the interaction between the TCR b chain
and the VSV peptide, summarized in Table 4.
Analysis of CDR3b sequences of TCRs that interact with the
wild-type VSV peptide showed that there was a highly conserved
G97(V/T)98 motif in almost all analyzed CDR3b loops (Table 1).
The occurrence of Gly at position 97 is interesting, in that Gly
provides maximal main chain flexibility. This may be used to
allow the CDR3b loop to access a number of different confor-
mations, which lead to productive binding interaction. The choice
of Gly, which lacks a side chain, may also allow for a closer
approach between the peptide and the CDR3b loop than would
other amino acids. The utilization of either Val or Thr at position
98 of the CDR3b loop suggests that this residue may be involved
in packing interactions with the wild-type VSV peptide. As Val
and Thr are isosteric, they can participate in very similar types of
van der Waals interactions. Further, because both residues are
b-branched amino acids, they may be responsible for enforcing a
particular conformation of the CDR3b loop. This idea is sup-
ported by the observation that the only other residue identified at
position 98 of the CDR3b loop is Ile, another b-branched amino
acid.
As is the case for the wild-type VSV peptide, a peptide-specific,
highly conserved motif can also be identified at position 97 and/or
position 98 of the CDR3b loop of TCRs that interact with the K6,
E6, and D6 peptides (Table 2). Further, we found that a charged
amino acid at position 6 of the VSV peptide always selected an
oppositely charged amino acid at position 98 of the CDR3b loop
(Table 2). Such results, along with the results obtained from
immunization with the wild-type VSV peptide, strongly suggest
that there is a specific interaction between the amino acid residue
at position 6 of the VSV peptide and the amino acid residue at
position 98 of the CDR3b loop.
Jorgensen et al. (8) were the first to use single-chain TCR
transgenic mice to map TCR-peptide contacts. Working in a
class II MHC system, they demonstrated that charge substi-
tutions in the moth cytochrome c peptide elicited reciprocal
changes in the CDR3b loop of TCRs. However, in this system,
charge substitutions (T3E or T3K) in the moth cytochrome
c peptide induced reciprocal charge changes at several differ-
ent positions within the CDR3b loop of TCRs. Therefore, the
data did not reveal a specific position as a peptide-contacting
site. In contrast, working in the class I MHC system, we found
that reciprocal charge changes in the CDR3b loop induced by
substitutions at position 6 of the VSV peptide always occurred
at position 98 of the CDR3b loop. Thus, for the VSVyH-2Kb
system, a particular amino acid residue within the TCR
CDR3b loop can be identified as a key peptide-interacting
residue for mediating the specificity of the interaction between
the TCR b chain and the antigenic peptides presented by MHC
molecules. The differences between our results and the results
of Jorgensen et al. (8) may reflect the fundamental differences
in modes of peptide binding and presentation found for the
class I and class II systems (29).
In contrast to our results, Turner et al. (11) did not find
reciprocal charge changes in the CDR3b loop of TCRs when they
immunized TCR a chain transgenic mice with charge variants of
the ovalbumin peptide, which is presented by H-2Kb. Given that
the same MHC molecule is used in our system and theirs, it is not
clear why different results were obtained. One reason may be the
difference in the antigenic peptides used in the two studies. In
particular, the existence of two adjacent charged amino acid
residues in the ovalbumin peptide (SIINFEKL) may prevent the
appearance of a simple reciprocal charge change in the CDR3b
loop of TCRs that recognize the altered peptides. Alternatively,
the different results may reflect the importance of using a TCR
a-deficient background to provide the necessary precision re-
quired for studying the interaction between the TCR b chain and
the antigenic peptide.
Our results suggest that the particular length of the CDR3b
loop is important for the recognition of the VSV peptide and its
variants. Three observations support this suggestion. First, all
sequenced CDR3b loops of TCRs recognizing the VSV peptide
were 9 amino acids in length (Table 1). Second, substitutions at
position 6 of the VSV peptide not only induced compensatory
changes in a specific residue within the CDR3b loop but also
increased the length of the CDR3b loop from 9 amino acids to
10–12 amino acids (Table 2). Third, substitutions at position 1 of
the VSV peptide, which did not induce compensatory sequence
changes in the CDR3b loop, also did not alter the 9-amino acid
length of the CDR3b loop (Table 3).
CDR3b loops have a great potential to vary in length due to
imprecise V–D and D–J joins and to the random addition of
nucleotides during the V–D–J rearrangement. In previous
studies, the length of the CDR3b loop was found to vary as a
function of the Vb and Jb usage (20), and a highly restricted
Vb–Jb response led to a conserved CDR3b loop length (30).
However, these observations cannot be used to explain our
results because we found that regardless of the Jb usage, the
length of the CDR3b loops of TCRs that interact with the VSV
peptide or its I1 and K1 variants was 9 amino acids in all cases
(Tables 1 and 3). Further, we demonstrated that the same
CDR3b length can be used by TCRs having different Vb
segments and that TCRs using the same Vb segment can have
different CDR3b lengths. Therefore, it can be concluded that
changes in the recombined germline segments are not respon-
sible for the alterations in the CDR3b length observed in our
study. Instead, we propose that the CDR3b length alters to
properly position the amino acid residue at position 98 of the
CDR3b loop so that this key residue can interact with the
amino acid residue at position 6 of the VSV peptide. It is
interesting that all observed alterations in the CDR3b length
were due to the addition of amino acid(s) C-terminal to the
conserved residue in the CDR3b loop.
In contrast to substitutions at position 6 of the VSV peptide,
substitutions at position 1 of the VSV peptide did not induce
Table 4. Changes in the CDR3b loop of TCRs induced by









VSV RGYVYQGL G VyT 9
K6 -----K-- R D 10 (11)
E6 -----E-- R 11 (12)
D6 -----D-- R 11 (12)
I1 I------- G VyT 9
K1 K------- G VyT 9
The single-letter code for each amino acid is used. For peptide
variants, only residues different from those of the VSV (wild-type)
peptide are shown. For peptide variants with substitutions at position
6 of the VSV peptide, the most common CDR3b loop length is listed,
with the second most common length shown in parentheses.
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changes in the CDR3b loop in terms of the amino acid motif at
positions 97 and/or 98 and the length of the CDR3b loop (Table
3). These results provide strong evidence that the amino acid
residue at position 1 of the VSV peptide does not interact with the
CDR3b loop. Given that position 1 and position 6 of the VSV
peptide are at the opposite ends of the VSV peptide, these results
suggest that the amino acid residues toward the C terminus of the
VSV peptide interact with the CDR3 loop of the TCR b chain,
whereas the amino acid residues toward the N terminus of the
peptide contact the CDR3 loop of the TCR a chain. Thus, our
study provides functional evidence for the current view of the
orientation of a TCR with its peptideyMHC ligand.
With the solution of the crystal structure of TCRypeptidey
MHC complexes, our knowledge of interactions between TCRs
and their cognate ligands has been greatly enriched (5, 6).
However, in vivo functional studies are needed to reveal the
biological importance of the interactions observed in the crystal
structures. Here, using TCR a transgenic mice in a TCR a-de-
ficient background as an analytic system, we demonstrated that
there was a specific interaction between the amino acid residue
at position 98 of the CDR3b loop of TCRs and the amino acid
residue at position 6 of the VSV peptide presented by H-2Kb.
Consistent with these findings, the crystal structure of a H-2Kb-
restricted, VSV peptide-specific TCR (31) showed that the amino
acid residue at position 98 of the CDR3b is at the apex of the loop
(Fig. 2), indicating that this residue is the most accessible residue
in the TCR b chain for contact with the exposed side chain(s) of
the peptide presented by an MHC molecule. The crystal structure
of two other class I MHC-restricted TCRs (5, 6) showed similar
results, even though the length of the CDR3b loop of these TCRs
is not the same. Thus, the three-dimensional structures are
consistent with the in vivo functional results, suggesting that the
amino acid residue at position 98 of the CDR3b loop is a key
residue for mediating the specificity of the interaction between
the TCR b chain and the antigenic peptides presented by the class
I MHC molecule.
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are labeled as b1, b2, and b3. Within CDR3b loop, the amino acid
residue at position 98 is shown in light blue at the apex of the loop;
other residues are shown in red. Figure is made with GRASP (32).
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